RxDoctor Payments Data

Khavar Dar, MD

Internal Medicine · Odessa, TXNPI 1669449617

Payments from drug & device makers

$584in general payments, 2019–2025

Across 37 payments — averaging $15.78 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Sunovion Pharmaceuticals Inc.$151
  • Novo Nordisk$102
  • GSK$64
  • Boehringer Ingelheim$55
  • Lilly USA, LLC$52
  • AbbVie$42
  • plus $119 from 5 others

What the payments were for

  • Food & beverage$584100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$584 in reported general payments places this provider in the 60th percentile of 7,675 internal medicine providers in Texas.

See all internal medicine providers in Texas

Medicare billing

Part B allowed, 2024
$206,640
Medicare patients
304
Services billed
1,946

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OfevNintedanib Esylate27$347,390
Prolastin CAlpha-1-Proteinase Inhibitor12$150,511
Trelegy ElliptaFluticasone/Umeclidin/Vilanter152$109,224
Breztri AerosphereBudesonide/Glycopyr/Formoterol97$84,616
TrulicityDulaglutide54$61,760
MounjaroTirzepatide45$54,693
OzempicSemaglutide32$38,782
JanuviaSitagliptin Phosphate22$22,100
LinzessLinaclotide15$20,475
EliquisApixaban29$19,299
Anoro ElliptaUmeclidinium Brm/Vilanterol Tr41$19,069
TrintellixVortioxetine Hydrobromide19$12,480
JardianceEmpagliflozin12$11,219
Breo ElliptaFluticasone/Vilanterol20$8,915
SymbicortBudesonide/Formoterol Fumarate25$6,985

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Boehringer IngelheimOfev, Jardiance$55$358,60939 claims
GSKTrelegy Ellipta, Anoro Ellipta, Breo Ellipta, Incruse Ellipta$64$141,131224 claims
Lilly USA, LLCTrulicity, Mounjaro$52$116,45499 claims
AstraZenecaBreztri Aerosphere, Symbicort, Pulmicort Flexhaler$34$95,996133 claims
Novo NordiskOzempic$102$38,78232 claims
AbbVieLinzess, Synthroid$42$21,54341 claims
Takeda Pharmaceuticals U.S.A., Inc.Trintellix$35$12,48019 claims
Johnson & JohnsonXarelto$16$6,16211 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 7,675 internal medicine providers in Texas.

Other internal medicine in Odessa

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →